• Lipoamino Bundle LNPs Enable Spleen-Targeted mRNA Transfecti

  2026-07-02

  This study introduces a new class of lipoamino bundle lipid nanoparticles (LNPs) that achieve efficient mRNA delivery and transfection in dendritic cells and macrophages, with pronounced spleen selectivity in vivo. The findings inform the rational design of targeted non-viral mRNA delivery platforms for immunological and therapeutic applications.

• Capsaicin as a Potent KDM1A/LSD1 Inhibitor in Gastric Cancer

  2026-07-02

  The referenced study identifies (E)-Capsaicin as a direct, reversible, and potent inhibitor of lysine-specific demethylase 1A (KDM1A/LSD1), with significant effects on epithelial–mesenchymal transition and cell invasion in gastric cancer models. This discovery introduces a novel epigenetic mechanism for capsaicin, expanding its research utility beyond TRPV1-mediated pain and inflammation signaling.

• HA-Coated siRNA Nanoparticles Target TDRD9 in P. aeruginosa

  2026-07-01

  A recent study demonstrates that hyaluronic acid-coated siRNA nanoparticles targeting Tudor domain-containing protein 9 (TDRD9) promote neutrophil cuproptosis and alleviate Pseudomonas aeruginosa-induced lung injury in preclinical models. This work establishes a novel immune modulation mechanism and suggests new therapeutic strategies for bacterial pneumonia leveraging extracellular matrix-based delivery.

• Bradykinin B2 Receptor Inhibition of Ileal Peristalsis: Mech

  2026-07-01

  This study provides the first direct evidence that bradykinin B2 receptors inhibit the peristaltic reflex in guinea pig isolated ileum, clarifying a key regulatory pathway in gastrointestinal motility. The findings establish a foundation for further research into the interplay between bradykinin pathways, ACE activity, and potential pharmacological interventions in gut physiology.

• EZ Cap Cy5 Firefly Luciferase mRNA: Precision for Quantitati

  2026-06-30

  Discover how EZ Cap Cy5 Firefly Luciferase mRNA (5-moUTP) revolutionizes quantitative mRNA delivery and intracellular tracking with dual-mode detection and optimized translation efficiency. This guide uniquely dissects advanced workflow design and assay decision-making for next-generation translational research.

• FAISL lncRNA Prevents FAK Proteolysis to Drive TNBC Progress

  2026-06-30

  This study reveals how the long noncoding RNA FAISL binds and stabilizes FAK protein by blocking Calpain 2-mediated degradation in triple negative breast cancer (TNBC). The findings demonstrate a novel regulatory axis that promotes tumor growth and metastasis, highlighting FAISL as a potential target for future TNBC therapies.

• Amikacin Disulfate: Applied Workflows for Antibiotic Mechani

  2026-06-29

  Amikacin disulfate, a semisynthetic aminoglycoside antibiotic, enables precise mapping of antibiotic mechanisms and resistance pathways through robust ribosomal and protein interaction studies. This article details optimized experimental workflows, advanced assay enhancements, and critical troubleshooting steps that leverage the latest structural and functional insights.

• Single-Molecule Imaging Reveals R-Loop–Replication Fork Coll

  2026-06-29

  This study utilizes single-molecule fluorescence imaging to directly observe how R-loops impede DNA replication by stalling the Phi29 DNA polymerase. The findings clarify the asymmetry and mechanistic basis of replication stress induced by R-loops, offering new insights for molecular biology research.

• Strategic p53 Inhibition: Cyclic Pifithrin-α in Translationa

  2026-06-28

  This thought-leadership article dissects the mechanistic value and translational potential of Cyclic Pifithrin-α hydrobromide as a precision tool for p53 pathway research. We bridge evidence from cancer biology and neuroinflammatory models, with protocol guidance and a forward-thinking outlook for translational researchers. The discussion integrates recent findings on Piezo2-mediated neuroinflammation in trigeminal neuralgia, positioning APExBIO's Cyclic Pifithrin-α hydrobromide as a versatile agent for dissecting apoptosis, cell survival, and pain modulation pathways.

• BHQ and SERCA Inhibition: Advancing HSC Mobilization Researc

  2026-06-27

  Explore how 2,5-di-tert-butylbenzene-1,4-diol (BHQ) is transforming calcium signaling and stem cell mobilization research. This article integrates mechanistic insights and strategic guidance, spotlighting recent breakthroughs in SERCA inhibition for translational and clinical workflows. See how innovative application of BHQ from APExBIO can propel your research beyond traditional boundaries.

• Applied Insights: Actinomycin D Workflows in Modern Research

  2026-06-26

  Actinomycin D (ActD) sets the benchmark for transcriptional inhibition and RNA stability assays—delivering robust, reproducible results in apoptosis induction and cancer research. Learn how to harness its unique properties in cutting-edge workflows, troubleshoot common pitfalls, and leverage new insights from cortical neurogenesis studies.

• Multianimal MRI Enhances Tumor Monitoring in Pancreatic Canc

  2026-06-26

  Kempinska et al. introduce an efficient multianimal MRI protocol for high-resolution tumor measurement in KPC pancreatic cancer mouse models. This workflow innovation reduces imaging time and cost, enabling reproducible longitudinal monitoring and robust preclinical evaluation of standard therapeutics such as Gemcitabine HCl.

• Cy5-UTP Enables Advanced RNA Phase Separation & Mitosis Insi

  2026-06-25

  Discover how Cy5-UTP (Cyanine 5-uridine triphosphate) empowers researchers to visualize RNA-driven phase separation and mitotic regulation. This article reveals unique applications of fluorescent RNA labeling in deciphering perichromosomal dynamics, offering a perspective not found in previous content.

• Dendritic Cell-Mediated Targeted Delivery of Amikacin to Gra

  2026-06-25

  This study demonstrates a novel strategy for delivering Amikacin directly into mycobacterial granulomas using monocyte-derived dendritic cells (DCs) as cellular vehicles. The approach enables localized antibiotic action against Mycobacterium avium while minimizing systemic toxicity, offering important implications for antibiotic resistance research and site-specific antibacterial therapy.

• DMXAA (Vadimezan): Advanced Protocols for Tumor Vascular Dis

  2026-06-24

  DMXAA (Vadimezan) is redefining cancer biology research as a potent vascular disrupting agent and apoptosis inducer in tumor endothelial cells. This article delivers actionable protocols, advanced troubleshooting, and translational insights, empowering researchers to maximize experimental reliability and mechanistic discovery.

16213 records 1/1081 page Next 12345 下5页 Last page